JP7789563B2 - Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 - Google Patents

Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療

Info

Publication number
JP7789563B2
JP7789563B2 JP2021568390A JP2021568390A JP7789563B2 JP 7789563 B2 JP7789563 B2 JP 7789563B2 JP 2021568390 A JP2021568390 A JP 2021568390A JP 2021568390 A JP2021568390 A JP 2021568390A JP 7789563 B2 JP7789563 B2 JP 7789563B2
Authority
JP
Japan
Prior art keywords
aptamer
dose
tlr
aptoll
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533966A (ja
JP2022533966A5 (https=
Inventor
デ ラ ペーニャ，デイビッド セガーラ
ゴマー，リサルド ボスカ
エルナンデス，イグナシオ リザソアイン
カストロ ソウブリエト，フェルナンド デ
サラゴサ，カルロス
ヒメネス，マカレナ エルナンデス
デル リオ，デイビッド ピニェイロ
ゴメス，ベアトリス フェルナンデス
サンチェス，マリア アンジェルス モロ
ロドリゲス，ディエゴ ペレス
リール，マリア ユージニア ザラボゾ
Original Assignee
メルク ヘルスケア コマンディトゲゼルシャフト アウフ アクティーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク ヘルスケア コマンディトゲゼルシャフト アウフ アクティーン filed Critical メルク ヘルスケア コマンディトゲゼルシャフト アウフ アクティーン
Publication of JP2022533966A publication Critical patent/JP2022533966A/ja
Publication of JP2022533966A5 publication Critical patent/JP2022533966A5/ja
Priority to JP2025117499A priority Critical patent/JP2025148491A/ja
Application granted granted Critical
Publication of JP7789563B2 publication Critical patent/JP7789563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021568390A 2019-05-16 2020-05-16 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療 Active JP7789563B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117499A JP2025148491A (ja) 2019-05-16 2025-07-11 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962849068P 2019-05-16 2019-05-16
US201962849072P 2019-05-16 2019-05-16
US62/849,068 2019-05-16
US62/849,072 2019-05-16
EP19382425 2019-05-27
EP19382424 2019-05-27
EP19382425 2019-05-27
EP19382424 2019-05-27
PCT/IB2020/054655 WO2020230109A1 (en) 2019-05-16 2020-05-16 Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117499A Division JP2025148491A (ja) 2019-05-16 2025-07-11 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療

Publications (3)

Publication Number Publication Date
JP2022533966A JP2022533966A (ja) 2022-07-27
JP2022533966A5 JP2022533966A5 (https=) 2023-05-25
JP7789563B2 true JP7789563B2 (ja) 2025-12-22

Family

ID=73288968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568390A Active JP7789563B2 (ja) 2019-05-16 2020-05-16 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JP2025117499A Pending JP2025148491A (ja) 2019-05-16 2025-07-11 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117499A Pending JP2025148491A (ja) 2019-05-16 2025-07-11 Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療

Country Status (7)

Country Link
US (2) US20220233572A1 (https=)
EP (1) EP3969011A1 (https=)
JP (2) JP7789563B2 (https=)
CN (1) CN113966220A (https=)
AU (1) AU2020276703A1 (https=)
CA (2) CA3140285A1 (https=)
WO (2) WO2020230109A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12390172B2 (en) * 2021-02-19 2025-08-19 Canon Medical Systems Corporation Method and apparatus for displaying medical images
WO2024064288A1 (en) * 2022-09-22 2024-03-28 Thomas Jefferson University Tlr4 inhibitors for cancer treatment
IL321911A (en) 2023-01-05 2025-09-01 Merck Patent Gmbh Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages
AU2024275027A1 (en) 2023-05-22 2025-12-11 Merck Patent Gmbh New tlr-4 antagonist aptamers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527260A (ja) 2014-06-24 2017-09-21 アプタス バイオテック，エス．エル． Ｔｌｒ−４特異的アプタマーおよびそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH088933B2 (ja) * 1987-07-10 1996-01-31 日本ゼオン株式会社 カテ−テル
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2619189B1 (en) 2010-09-24 2020-04-15 Zoetis Services LLC Isoxazoline oximes as antiparasitic agents
WO2020069313A2 (en) * 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527260A (ja) 2014-06-24 2017-09-21 アプタス バイオテック，エス．エル． Ｔｌｒ−４特異的アプタマーおよびそれらの使用

Also Published As

Publication number Publication date
JP2022533966A (ja) 2022-07-27
WO2020230108A1 (en) 2020-11-19
CN113966220A (zh) 2022-01-21
US20220233572A1 (en) 2022-07-28
CA3291318A1 (en) 2026-03-02
CA3140285A1 (en) 2020-11-19
JP2025148491A (ja) 2025-10-07
EP3969011A1 (en) 2022-03-23
US20220233570A1 (en) 2022-07-28
WO2020230109A1 (en) 2020-11-19
AU2020276703A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7789563B2 (ja) Ｔｌｒ－４を標的とするアプタマーによるｔｌｒ－４媒介性の疾患および状態の治療
JP7398007B2 (ja) Ａｎｇｐｔｌ３発現を阻害する組成物及び方法
EP3992290A1 (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
PT2596807E (pt) Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
CN104145018B (zh) 新型C5a结合性核酸
Tan et al. Host molecules regulating neural invasion of Zika virus and drug repurposing strategy
TW202016303A (zh) 用於減少ｆｘｉ表現之化合物及方法
WO2022121959A1 (zh) siRNA分子及其在治疗冠状动脉疾病中的应用
AU2018269935B2 (en) Compositions and methods for the treatment of complications and disorders relating to von Willebrand factor
JP2025163035A (ja) 筋再生および筋成長
US20240279667A1 (en) Compositions and methods of treating diseases associated with bile acid transporter
US12458657B2 (en) Neurogenesis
Guo et al. HMGB1: from molecular functions to clinical applications in cancer and inflammatory diseases
JP2023093504A (ja) 活性成分としてｔｓｐ１タンパク質インヒビターを含有する、ファブリー病を予防または処置するための医薬組成物
AU2013355043A1 (en) Oligonucleotide formulation
TW202540420A (zh) 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
TW202220675A (zh) 降低ｚ－ａａｔ蛋白水準之方法
WO2023167336A1 (ja) 線維化疾患の治療又は予防のための医薬組成物
WO2025252223A1 (zh) 一种抑制PCSK9基因表达的RNAi制剂及其应用
WO2026061490A1 (zh) 用于抑制FXII基因表达的siRNA及其缀合物和用途
JP2025512445A (ja) Ｓｃａｐ活性を調節するための組成物及び方法
JP2024537874A (ja) Ａｄａｍｔｓ１４阻害
CN118922540A (zh) 前激肽释放酶调节组合物及其使用方法
WO2025231388A1 (en) Methods and compositions for treating pompe disease
HK40115827A (zh) 用於抑制ldha表达的方法和组合物

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250311

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251210

R150 Certificate of patent or registration of utility model

Ref document number: 7789563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150